Cellectis SA (ALCLS) Price & Analysis

Q: What was Cellectis SA’s price range in the past 12 months?

Cellectis SA lowest stock price was €1.01 and its highest was €4.84 in the past 12 months.

Q: What is Cellectis SA’s market cap?

Cellectis SA’s market cap is $211.96M.

Q: When is Cellectis SA’s upcoming earnings report date?

Cellectis SA’s upcoming earnings report date is Mar 11, 2026 which is in 113 days.

Q: How were Cellectis SA’s earnings last quarter?

Cellectis SA released its earnings results on Nov 07, 2025. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.198 by €0.207.

Q: Is Cellectis SA overvalued?

According to Wall Street analysts Cellectis SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Cellectis SA pay dividends?

Cellectis SA does not currently pay dividends.

Q: What is Cellectis SA’s EPS estimate?

Cellectis SA’s EPS estimate is -0.27.

Q: How many shares outstanding does Cellectis SA have?

Cellectis SA has 72,093,636 shares outstanding.

Q: What happened to Cellectis SA’s price movement after its last earnings report?

Cellectis SA reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.198. Following the earnings report the stock price went up 12.238%.

Q: Which hedge fund is a major shareholder of Cellectis SA?

Currently, no hedge funds are holding shares in FR:ALCLS

Compare

1 Followers

ALCLS Stock Chart & Stats

€3.70

-€0.02(-1.32%)

At close: Jan 09 4:00 PM EST

€3.70

-€0.02(-1.32%)

Day’s Range― - ―

52-Week Range€1.01 - €4.84

Previous CloseN/A

Volume10.86K

Average Volume (3M)852.48K

Market Cap

$211.96M

Enterprise Value€56.58M

Total Cash (Recent Filing)$196.15M

Total Debt (Recent Filing)$94.77M

Price to Earnings (P/E)―

Beta2.14

Next Earnings

Mar 11, 2026

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding72,093,636

10 Day Avg. Volume1,338,181

30 Day Avg. Volume852,477

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.16

Price to Sales (P/S)3.65

P/FCF Ratio7.92

Enterprise Value/Market Cap0.27

Enterprise Value/Revenue1.01

Enterprise Value/Gross Profit1.09

Enterprise Value/Ebitda-1.87

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Cellectis SA News

Cellectis reports Q3 adjusted EPS 2c vs (22c) last year

Reports Q3 revenue $35.17M vs 16.2M last year. “We are proud of the promising data from our core...

11d ago

CLLS

Cellectis to present development update for eti-cel at ASH 2025

Cellectis (CLLS) announced the acceptance of two abstracts for poster presentation at the American Society of Hematology, ASH,...

15d ago

CLLS

Cellectis price target raised to $4 from $3 at Wells Fargo

Wells Fargo analyst Nick Abbott raised the firm’s price target on Cellectis (CLLS) to $4 from $3 and...

29d ago

CLLS

Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones

JonesTrading analyst Soumit Roy has maintained their neutral stance on CLLS stock, giving a Hold rating today. Soumit...

7d ago

CLLS

CMVLF Upcoming Earnings Report: What to Expect?

Cellectis SA (CMVLF) is scheduled to report 3rd quarter earnings on 11/07/2025, after the market closes. Regarding Q3...

13d ago

Cellectis price target raised to $8 from $4 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Cellectis (CLLS) to $8 from $4 and keeps...

1M ago

CLLS

Cellectis SA’s Promising Study on UCART20x22 for B-Cell Non-Hodgkin Lymphoma

Cellectis SA (($CMVLF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled Open-label...

2M ago

CMVLF

Cellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations

JonesTrading analyst Soumit Roy has maintained their neutral stance on CLLS stock, giving a Hold rating on August...

3M ago

CLLS

Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment

Cellectis S.A. (($CLLS)), Cellectis SA (($CMVLF)) announced an update on their ongoing clinical study. In a recent update,...

3M ago

CLLS

Cellectis Reports Q2 2025 Results and Strategic Updates

Cellectis SA ( ($CMVLF) ) has released its Q2 earnings. Here is a breakdown of the information Cellectis...

3M ago

CMVLF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Cellectis SA (CMVLF) is scheduled to report 2nd quarter earnings on 08/04/2025, after the market closes. Regarding Q2...

4M ago

Cellectis files $200M mixed securities shelf

16:20 EDT Cellectis (CLLS) files $200M mixed securities shelf Published first on TheFly – the ultimate source for...

5M ago

CLLS

Cautious Hold on Cellectis SA Amid Anticipated Data Releases and Strategic Developments

JonesTrading analyst Soumit Roy has reiterated their neutral stance on CLLS stock, giving a Hold rating on May...

6M ago

CLLS

Cellectis SA: Hold Rating Amid Stable Financials and Promising Collaborations, Yet Cautious Outlook Due to Market and Clinical Uncertainties

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Hold rating on Cellectis SA (CLLS...

6M ago

CLLS

ALCLS FAQ

What was Cellectis SA’s price range in the past 12 months?

Cellectis SA lowest stock price was €1.01 and its highest was €4.84 in the past 12 months.

What is Cellectis SA’s market cap?

Cellectis SA’s market cap is $211.96M.

When is Cellectis SA’s upcoming earnings report date?

Cellectis SA’s upcoming earnings report date is Mar 11, 2026 which is in 113 days.

How were Cellectis SA’s earnings last quarter?

Cellectis SA released its earnings results on Nov 07, 2025. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.198 by €0.207.

Is Cellectis SA overvalued?

According to Wall Street analysts Cellectis SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cellectis SA pay dividends?

Cellectis SA does not currently pay dividends.

What is Cellectis SA’s EPS estimate?

Cellectis SA’s EPS estimate is -0.27.

How many shares outstanding does Cellectis SA have?

Cellectis SA has 72,093,636 shares outstanding.

What happened to Cellectis SA’s price movement after its last earnings report?

Cellectis SA reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.198. Following the earnings report the stock price went up 12.238%.

Which hedge fund is a major shareholder of Cellectis SA?

Currently, no hedge funds are holding shares in FR:ALCLS

Company Description

Cellectis SA

Cellectis SA is a biotechnology company based in France that focuses on developing innovative therapies for cancer and genetic diseases using its proprietary gene-editing technology. The company specializes in the development of CAR-T cell therapies, which are designed to harness the power of the immune system to target and eliminate cancer cells. Cellectis operates primarily in the healthcare sector, with its core products and services centered around its unique gene-editing platform, UCART, and collaborations with various pharmaceutical companies to advance its therapies into clinical development.

Cellectis SA (ALCLS) Earnings & Revenues

Historic Earnings Reports

ALCLS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all FR:ALCLS earnings summaries